CombiPatch / Climara Pro and Cannabis: The Full Drug Interaction Profile for Women

What Are CombiPatch and Climara Pro?

CombiPatch and Climara Pro are transdermal combination hormone therapy (HT) patches approved by the FDA for treating moderate-to-severe vasomotor symptoms and vulvovaginal atrophy in women with an intact uterus. Each patch delivers estradiol alongside a progestin, which is required to protect the uterine lining from estrogen-driven overgrowth.

CombiPatch pairs estradiol with norethindrone acetate (NETA) and is worn twice weekly. Climara Pro pairs estradiol with levonorgestrel (LNG) and is changed once weekly. Both deliver hormones directly through the skin, bypassing first-pass liver metabolism, which is a pharmacokinetic point that matters a great deal when you are thinking about cannabis interactions.

The FDA prescribing information for CombiPatch lists thromboembolism, breast cancer, endometrial cancer, and cardiovascular disease as the major safety concerns. Climara Pro carries the same class warnings under the FDA boxed label for estrogen-progestin therapy.

Who Uses These Patches and Why It Matters

These are menopausal and perimenopausal medications. The average woman starting combination transdermal HT is in her late 40s to mid-50s, often managing hot flashes, night sweats, sleep disruption, and genitourinary symptoms of menopause (GSM). The Menopause Society (formerly NAMS) 2023 Position Statement confirms that for healthy women under 60 who are within 10 years of menopause onset, the benefits of HT outweigh the risks for vasomotor symptoms. Cannabis use is also rising sharply in this same demographic. A 2023 analysis in Menopause found that cannabis use among women aged 45 to 64 increased by more than 300% between 2002 and 2019. These two trends are now colliding in clinical practice.

How Transdermal Delivery Changes the Interaction Math

Before looking at cannabis specifically, you need to understand why the patch route matters pharmacokinetically.

Oral estradiol goes through the liver before reaching systemic circulation, making it highly susceptible to any drug that alters hepatic enzymes. Transdermal estradiol largely bypasses that first pass. A pharmacokinetic study published in Climacteric confirmed that transdermal estradiol produces lower peak hepatic estradiol exposure and is less affected by enzyme-inducing or enzyme-inhibiting drugs compared to oral formulations.

This is genuinely reassuring for cannabis users: the interaction risk with transdermal estradiol is lower than it would be with oral estradiol pills or rings that release hormone absorbed orally.

The progestins in these patches (NETA and LNG) are also delivered transdermally, though both undergo some hepatic metabolism after absorption. NETA is converted partly to ethinyl estradiol in the gut wall and liver; LNG is metabolized primarily via CYP3A4 and CYP2C9.

Cannabis Pharmacology: What THC and CBD Actually Do to Liver Enzymes

Cannabis contains dozens of active compounds. For drug interaction purposes, two matter most: delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD).

CBD and CYP3A4 Inhibition

CBD is a clinically meaningful inhibitor of CYP3A4, the enzyme responsible for metabolizing a wide range of drugs including the progestin components of combination HT patches. A 2020 paper in Clinical Pharmacokinetics characterized CBD as a competitive and mechanism-based inhibitor of CYP3A4 and CYP2C9. At the high oral doses used in Epidiolex (the prescription CBD product, 5 to 20 mg/kg/day), this inhibition is clinically significant. At the lower doses in typical recreational or wellness cannabis products, the inhibition is present but quantitatively smaller.

For a woman using a CombiPatch or Climara Pro, CYP3A4 inhibition by CBD could theoretically slow clearance of LNG or NETA after they enter systemic circulation, potentially raising progestin exposure modestly. Whether this translates to any clinical effect, such as more progestin-related side effects like bloating or mood changes, is unknown because no trial has looked at this directly.

THC, CYP1A2, and Estradiol

THC has a more complex and less predictable enzyme profile. Research published in Drug Metabolism and Disposition showed that cannabinoids can induce CYP1A2, one of the enzymes that hydroxylates estradiol to less active metabolites. Chronic heavy cannabis smoking may therefore slightly increase estradiol clearance via this route. Again, the transdermal bypass of first-pass metabolism reduces, but does not eliminate, this concern.

Protein Binding Competition

Both THC and CBD are highly protein-bound (greater than 97%). Estradiol and synthetic progestins also bind to sex hormone-binding globulin (SHBG) and albumin. A review in the British Journal of Clinical Pharmacology noted that protein-binding displacement interactions between cannabinoids and steroid hormones are theoretically possible but have not been shown to be clinically important in human studies at typical cannabis doses.

Pharmacodynamic Interactions: Beyond the Liver

Pharmacodynamic interactions happen when two drugs affect the same body system, regardless of enzyme pathways.

CNS Effects

Both estradiol and cannabis modulate the central nervous system. Estrogen has well-documented effects on serotonin, dopamine, and GABA signaling. A 2021 review in Frontiers in Neuroendocrinology described how estrogen and the endocannabinoid system interact at the receptor level, particularly in the hypothalamus and limbic system. This overlap means that cannabis may amplify or blunt some HT-related CNS effects, including mood stabilization and sleep architecture changes, though the direction is variable and dose-dependent.

For women using HT partly to manage perimenopausal mood disturbance or insomnia, adding cannabis introduces unpredictability. Some women report relief; others report increased anxiety, particularly with high-THC products.

Cardiovascular Considerations

The Menopause Society 2023 Position Statement notes that transdermal estradiol may carry a lower venous thromboembolism (VTE) risk than oral estrogen. Cannabis, particularly with acute heavy use, transiently increases heart rate and can affect platelet aggregation. A 2019 statement from the American Heart Association flagged cannabis as a potential cardiovascular risk factor, especially in women with pre-existing cardiac risk. Women on combination HT who smoke cannabis regularly should discuss their individual cardiovascular profile with their clinician.

A Clinical Framework for Assessing Cannabis Risk by Use Pattern

Because no trial has studied this interaction directly, a practical framework based on known pharmacology is more useful than a blanket warning:

Low-risk pattern: Occasional use (once weekly or less), low-THC or balanced THC:CBD products, inhaled or sublingual route, no other CYP3A4 inhibitors or inducers, no personal cardiovascular risk factors. Interaction risk with CombiPatch or Climara Pro is likely minimal.

Moderate-risk pattern: Several times per week use, high-CBD oral products (edibles, tinctures at 50 mg or more of CBD daily), or concurrent use of other CYP-active medications. Progestin exposure may be modestly elevated. Monitor for progestin-related side effects.

Higher-risk pattern: Daily heavy use, high-THC concentrates, personal history of VTE, cardiovascular disease, uncontrolled hypertension, or migraine with aura. The pharmacodynamic cardiovascular risk compounds the modest pharmacokinetic uncertainty. A frank conversation with your prescriber is warranted before continuing both.

Can You Drink Alcohol on CombiPatch or Climara Pro?

Many women ask about alcohol alongside cannabis, so it is worth covering both.

Alcohol acutely raises circulating estradiol levels. A pharmacokinetic study in the Journal of the National Cancer Institute found that even moderate alcohol consumption (one to two drinks) raised plasma estradiol by up to 327% in postmenopausal women on oral HT. The effect is smaller with transdermal HT because the patch bypasses hepatic first-pass alcohol-enzyme competition, but a transient rise in free estradiol still occurs.

Combining alcohol and cannabis on the same evening adds CNS depression. Alcohol plus THC together produce more pronounced impairment than either alone, a pharmacodynamic interaction documented in driving simulation research. This combination is not specific to HT users but is worth naming explicitly.

For women on CombiPatch or Climara Pro, light-to-moderate alcohol (up to one drink per day) is not contraindicated, but heavy or binge drinking raises both estrogen exposure and breast cancer risk over time. Regular heavy alcohol is an independent contraindication consideration for HT continuation.

Female-Specific Conditions That Change the Calculus

PCOS

Women with PCOS who have been prescribed combination HT in perimenopause often have baseline insulin resistance and a different endocannabinoid system tone. A 2021 study in the Journal of Clinical Endocrinology and Metabolism found altered endocannabinoid levels in women with PCOS compared to controls. Whether cannabis modifies HT response differently in PCOS is entirely unstudied.

Endometriosis and Fibroids

Both conditions are estrogen-sensitive. Women with a history of endometriosis or fibroids who use combination HT in menopause are already balancing a fine therapeutic margin. Any factor that substantially alters progestin or estrogen exposure, including heavy CBD use, deserves extra caution given the estrogen-driven nature of these conditions.

Female Pattern Hair Loss

LNG (in Climara Pro) has androgenic properties. Some women with androgenic alopecia or hormonally-sensitive hair loss switch to NETA-containing patches specifically to minimize androgenic load. Cannabis does not appear to have a direct androgenic pathway interaction, but its effect on SHBG is poorly characterized. Lower SHBG means more free androgens, and chronic heavy cannabis use has been associated with modest changes in sex hormone profiles in some small studies.

Pregnancy, Lactation, and Contraception

This section is required and applies directly to any woman reading this who has questions about her reproductive status.

Pregnancy: Both CombiPatch and Climara Pro are FDA Pregnancy Category X, meaning known or suspected fetal harm and risks that outweigh any possible benefit. Exogenous estrogen-progestin combinations carry risks of congenital anomalies when used in early pregnancy, based on older oral contraceptive data. If there is any possibility you could be pregnant, do not use these patches and speak with your clinician immediately.

Cannabis in pregnancy is independently contraindicated. ACOG Committee Opinion 722 states that cannabis use during pregnancy is associated with adverse birth outcomes including low birth weight and preterm delivery. Combining hormonal patches with cannabis during pregnancy is a scenario that should simply not occur.

Lactation: CombiPatch and Climara Pro are not approved for use in breastfeeding women. Estrogen can suppress milk production, and progestins transfer into breast milk. Cannabis is also contraindicated during breastfeeding. ACOG recommends that women who are breastfeeding discontinue cannabis use, as THC concentrates in breast milk and may affect infant neurodevelopment.

Contraception note: These patches provide no contraceptive protection. Perimenopausal women who are still ovulating intermittently remain at risk for pregnancy. If you are in early perimenopause and sexually active, discuss reliable contraception with your clinician. Hormonal contraception may be more appropriate at this stage than menopausal HT.

Who This Is Right For, and Who Should Be More Cautious

Women Who Are Likely Fine Using Occasional Cannabis on These Patches

You are postmenopausal (at least 12 months since last period), you use cannabis occasionally (once or twice a week, modest doses), you have no personal history of VTE or cardiovascular disease, you are not taking other strong CYP3A4 inhibitors (like ketoconazole or clarithromycin), and your breast cancer risk is not elevated. Your interaction risk is low based on current pharmacokinetic reasoning.

Women Who Should Discuss This With Their Prescriber First

You use CBD oil daily at doses above 50 mg, you smoke or vape cannabis heavily (daily), you have a personal history of VTE, atrial fibrillation, or significant cardiovascular disease, you are still in early perimenopause and your ovulation status is uncertain, or you are taking other medications with narrow therapeutic windows that share CYP3A4 metabolism. In these situations, the absence of trial data means your clinician needs to weigh the specifics of your case.

Women Who Should Reconsider the Combination

You have a personal or strong family history of hormone-receptor-positive breast cancer, you have a history of stroke or migraine with aura, or you have active liver disease. These are already situations where HT itself requires careful risk-benefit discussion. Adding cannabis does not make any of these safer.

The Evidence Gap: A Candid Assessment

Women have been systematically underrepresented in pharmacokinetic drug interaction research, and this topic is a clear example. There are no published RCTs examining cannabis interaction with transdermal combination HT. There are no large observational cohort studies. The evidence is entirely extrapolated from:

1. Enzyme inhibition studies done in vitro or in oral-drug contexts
2. General cannabinoid pharmacokinetic literature (much of it in men or mixed-sex cohorts)
3. First-principles reasoning about transdermal bypass of hepatic metabolism

A 2020 commentary in Menopause calling for rigorous study of cannabis in menopausal women noted that clinicians are already fielding these questions daily without adequate data to answer them. That gap is real, and you deserve to know it exists rather than receiving false confidence in either direction.

What can be said with reasonable confidence: the transdermal route meaningfully reduces, though does not eliminate, the hepatic enzyme interaction risk compared to oral HT. Occasional low-dose cannabis is pharmacokinetically unlikely to produce a clinically significant change in patch hormone delivery for most women.

What cannot be said: whether specific cannabis use patterns, product types, or individual genetic variation in CYP enzymes (such as CYP3A4 poor metabolizers) produce meaningful hormonal disruption in real women. This is an area where the field owes women better research.

Practical Guidance Before Your Next Refill Conversation

Tell your prescriber or NP specifically what cannabis products you use, how often, at what dose, and by what route. Inhaled cannabis has different PK than high-dose oral CBD tinctures. "I use cannabis sometimes" is not enough clinical detail.

If you are using CBD for sleep or anxiety alongside your patch, consider whether addressing these symptoms through your HT management directly, or through evidence-based options your clinician can prescribe, would be preferable to an unstudied combination.

Monitor for any change in your HT symptom control after starting or increasing cannabis use. A return of hot flashes or unexpected breakthrough spotting (which should always be evaluated) could in theory relate to altered hormone levels, though many other explanations are more likely.

The Menopause Society's 2023 Position Statement does not address cannabis specifically, but its emphasis on individualized risk-benefit assessment applies here. Your prescriber should be a partner in this conversation, not a gatekeeper who dismisses the question.